This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Company News for Jan 23, 2020
by Zacks Equity Research
Companies in the news are: FSB, AKCA, ALLY, MRNA
Akcea Therapeutics (AKCA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 38.18% and 39.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Akcea Therapeutics (AKCA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akcea Therapeutics (AKCA) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Akcea Therapeutics (AKCA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What's in Store for Align Technology's (ALGN) Q3 Earnings?
by Zacks Equity Research
We are optimistic that Align Technology's (ALGN) Invisalign product portfolio has shown continued strength in the third quarter.
Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.
Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings?
by Zacks Equity Research
Illumina (ILMN) is taking a cautious approach after a disappointing second quarter.
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?
by Zacks Equity Research
The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.
Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.
Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.
Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates
by Zacks Equity Research
Key highlights of the past week include label expansion of drugs, licensing deals and more.
Akcea Therapeutics Enters Oversold Territory
by Zacks Equity Research
Akcea Therapeutics, Inc. (AKCA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Akcea Therapeutics (AKCA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -5.26% and -34.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Akcea Therapeutics (AKCA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akcea Therapeutics (AKCA) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -72.58% and -7.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Akcea Therapeutics (AKCA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akcea Therapeutics (AKCA) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer Gets FDA's Priority Review for Rare Disease Candidate
by Zacks Equity Research
FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.
Akcea Therapeutics (AKCA) Q2 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Akcea (AKCA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Akcea (AKCA) stock based on the movements in the options market lately.
Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA
by Zacks Equity Research
Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.
Is the Options Market Predicting a Spike in Akcea Therapeutics (AKCA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Akcea Therapeutics (AKCA) stock based on the movements in the options market lately.
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
by Zacks Equity Research
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
Are Options Traders Betting on a Big Move in Akcea Therapeutics (AKCA) Stock?
by Zacks Equity Research
Investors in Akcea Therapeutics (AKCA) need to pay close attention to the stock based on moves in the options market lately.
Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) will independently develop Inotersen and IONIS-FB-L Rx as GlaxoSmithKline declines its option on both drugs.